ORPP logo

Irritable Bowel Syndrome. (Record no. 59780)

MARC details
000 -LEADER
fixed length control field 07450nam a22004813i 4500
001 - CONTROL NUMBER
control field EBC3018614
003 - CONTROL NUMBER IDENTIFIER
control field MiAaPQ
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20240729124104.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr cnu||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 240724s2009 xx o ||||0 eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781608769636
Qualifying information (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN 9781606929308
035 ## - SYSTEM CONTROL NUMBER
System control number (MiAaPQ)EBC3018614
035 ## - SYSTEM CONTROL NUMBER
System control number (Au-PeEL)EBL3018614
035 ## - SYSTEM CONTROL NUMBER
System control number (CaPaEBR)ebr10661552
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)923658876
040 ## - CATALOGING SOURCE
Original cataloging agency MiAaPQ
Language of cataloging eng
Description conventions rda
-- pn
Transcribing agency MiAaPQ
Modifying agency MiAaPQ
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC862.I77 -- I77 2009eb
082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.342
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Driggers, Jonathon D.
245 10 - TITLE STATEMENT
Title Irritable Bowel Syndrome.
250 ## - EDITION STATEMENT
Edition statement 1st ed.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Hauppauge :
Name of producer, publisher, distributor, manufacturer Nova Science Publishers, Incorporated,
Date of production, publication, distribution, manufacture, or copyright notice 2009.
264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice ©2009.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (209 pages)
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Intro -- IRRITABLE BOWEL SYNDROME -- IRRITABLE BOWEL SYNDROME -- Contents -- Preface -- Chapter I Pathway for the Development of Drugs to Treat Irritable Bowel Syndrome: From Molecule Identification through Approval -- Abstract -- Introduction -- Molecule Identification and Preclinical Evalutions -- Pharmacodynamic Studies (Phase 1b) -- Phase 2 (2a and 2b) -- Phase 3 Program -- Selection of Clinical Trial Endpoints -- Health Economics -- Conclusions -- References -- Chapter II The New Epidemiology of Inflammatory Bowel Diseases: Changing Trends and Causes -- Abstract -- Incidence of Inflammatory Bowel Diseases: Changing Trends -- North America and Western Europe -- Eastern Europe -- Asia, Middle-East, Australia and Central-South America -- Middle-East -- What are the Factors Behind the Epidemiology Trends? -- References -- Chapter III Neuroendocrine and Immune Interactions in Irritable Bowel Syndrome -- Introduction -- The Hypothalamic-Pituitary-Adrenal Axis -- Hypothalamic-Pituitary-Adrenal Axis Dysfunction in IBS -- Immune Activation in IBS -- Immune Activation and Serotonin -- The Potential Impact of Childhood Trauma on Neuroendocrine and Immune Functioning in IBS -- References -- Chapter IV Impact of Oxidative Stress on Diabetes Mellitus and Inflammatory Bowel Diseases -- Abstract -- 2. Introduction -- 2.1 ROS under Physiological Conditions -- 2.2 ROS under Pathological Conditions -- 2.3 Antioxidant Defence of Human Organism -- 2.4 Some Remarks to Antioxidant Enzymes and Substances from the Recent Literature -- 2.5 Non-enzymatic Substances of Endogenous or Exogenous Origin -- Thioredoxin (Trx) -- Coenzyme Q10 (CoQ) -- Vitamin C -- Vitamin E -- Phytochemicals -- 2.6 Catalytic Antioxidants - New Therapeutic Possibilities -- 3. DNA Oxidative Damage and DNA Repair -- Nuclear DNA Damage and Repair.
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note MItochondrial DNA Damage and Repair -- 3.3 Poly(ADP-ribose) Polymerase -- 3.4 Diseases Related with Oxidative Stress and DNA Damage -- 4. Oxidative Stress and Pathophysiology of Diabetes Mellitus and Inflammatory Bowel Diseases -- 4.1 Diabetes Mellitus -- 4.1.1 ROS and Diabetes -- ROS, DNA Damage and DM -- ROS, DNA Repair and DM -- Some Contributions to Antioxidant Therapy in Diabetes Mellitus -- 4.2 Crohn´s Disease -- ROS and IBD -- ROS, DNA Damage, DNA Repair and IBD -- 5. Our Study Examining Oxidative Stress, DNA Damage and DNA Repair in Patients with Diabetes Mellitus and Crohn Disease -- 5.1 Hypothesis -- 5.2 Study Material -- 5.3 Methods -- 5.4 Results -- 5.4.2 Comparison of T1DM Patients versus Healthy Population -- The findings of lower GPx and AOC and high MDA both in adults and children with T1DM correspond with the results of other authors [130, 175, 176]. Results of patients with T2DM showed stimulation of antioxidant enzymes and low GSH. Low MDA could be explain5.4.1 Study of Oxidative Stress, DNA Damage and DNA Repair Capacity of Lymphocytes in Healthy Adults and Healthy Children -- 5.4.3 Comparison of T1DM Adult Group versus T1DM Children -- 5.4.4 Comparison of T1DM Adults Divided into 2 Subgroups Based on the Abscence or Presence of Diabetic Microvascular Complications with T1DM Children (Published by Varvarovska, Biomedicine and Pharmacotherapy 2004, Citation 136) -- 5.4.5 Study of CD Patients (Adults and Children) versus Healthy Adult Population -- 5.4.6 Comparison of Adult CD Patients with CD Children -- 5.4.7 Comparison of Adult Diabetic Patients and Patients with Crohn's Disease -- 5.4.8 Children with T1DM and CD Compared with Healthy Children -- 5.4.10 Comparison of all Groups of Patients versus Healthy Adults -- Conclusion -- Acknowledgments -- References.
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note Chapter V Adverse Effects of Corticosteroid Therapy in Inflammatory Bowel Disease -- Abstract -- Introduction -- Mechanisms of Actions of Corticosteroids -- Corticosteroid Formulations Used in Inflammatory Bowel Disease -- Adverse Effects of Corticosteroid Therapy in Inflammatory Bowel Disease (Corticosteroid Toxicity) -- Metabolic and Endocrine -- Hyperglycemia, Diabetes Mellitus -- Hypertension -- Hyperlipidemia -- Alteration of Fat Distribution (Cushingoid Appearance, Buffalo Hump, Central Obesity, Weight Gain) -- Fluid Retention and Electrolyte Imbalance -- Fluid and Sodium Retention -- Hypokalemia -- Hypocalcemia -- Gynecological/ Sex Hormones -- Adrenal Suppression -- Ocular -- Cataract -- Glaucoma -- Gastrointestinal Complications -- Peptic Ulcer -- Pancreatitis -- Hepatic Steatosis -- Cutaneous -- Psychiatric Side Effects -- Neurologic Side Effects -- Musculoskeletal -- Osteopenia and Osteoporosis -- Osteonecrosis -- Myopathy -- Hematopoietic and Immulologic -- Infections -- Growth Retardation -- Pregnancy and Lactation -- Mortality by Corticosteroids in IBD Patients -- Quality of Life in Corticosteroid-Treated Patients -- How to Reduce or Avoid Corticosteroid-Related Adverse Events -- Conclusion -- Conflicts of Interest -- References -- Short Communication A Is Colonic Hypersensitivity Really a Biological Marker of Irritable Bowel Syndrome (IBS)? -A Role of Visceral Sensitivity on Pathophysiology of IBS. -- Introduction -- Possible Mechanism of Visceral Hypersensitivity in IBS -- Relationships between Visceral Hypersensitivity and Clinical IBS Symptoms -- Future directions -- References -- Short Communication B Spasmolytics in Irritable Bowel Syndrome a Meta-Analysis of their Controlled Clinical Trials -- Abstract -- Acknowledgments -- References.
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note Short Communication C Interviewer-Assisted Questionnaire Administration: An Innovation to Circumvent the Validation of the Rome Criteria in Resource-Limited Multicultural Settings -- Abstract -- Background -- Methods -- Results -- Conclusion -- References -- Index.
588 ## - SOURCE OF DESCRIPTION NOTE
Source of description note Description based on publisher supplied metadata and other sources.
590 ## - LOCAL NOTE (RLIN)
Local note Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Irritable colon.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Colon (Anatomy) -- Diseases.
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Pellegrino, Calvin A.
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Print version:
Main entry heading Driggers, Jonathon D.
Title Irritable Bowel Syndrome
Place, publisher, and date of publication Hauppauge : Nova Science Publishers, Incorporated,c2009
International Standard Book Number 9781606929308
797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN)
Corporate name or jurisdiction name as entry element ProQuest (Firm)
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3018614">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3018614</a>
Public note Click to View

No items available.

© 2024 Resource Centre. All rights reserved.